Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
om-85 (OM Pharma)
- Development stage
- Phase 4
- Lead developer
- OM Pharma
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
OM-85 (marketed as Broncho Vaxom) is an oral immunostimulant composed of lyophilized bacterial lysates from multiple respiratory pathogens, including *Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Klebsiella pneumoniae* and others. It is used primarily for the prevention and treatment of recurrent respiratory tract infections and acute exacerbations of chronic bronchitis. The drug acts by modulating both innate and adaptive immune responses—stimulating cytokine production (such as IL-1, IL-6, TNF-alpha), activating dendritic cells via NF-kB and MAPK pathways (notably Erk1/2), enhancing B-cell activation (via BAFF and APRIL), increasing chemokine release to recruit immune effector cells (CXCL8/IL-8), promoting NK cell activity, and boosting mucosal immunity. These effects result in reduced frequency of respiratory infections and decreased antibiotic use in susceptible populations[1][4][6]. OM-85 is not approved in the United States but is widely used internationally.
- Brand names
- Broncho Vaxom
- Other names
- BVBroncho-Vaxom
02
Targets
NF-κB
Beyond the preview
Go deeper on om-85 (OM Pharma).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on om-85 (OM Pharma).